MaxPoint Interactive to Speak at the Needham Emerging Technology Conference

RALEIGH, N.C.--(BUSINESS WIRE)-- MaxPoint (NYSE: MXPT), the company that helps manufacturers and retailers generate in-store sales with its innovative Digital Zip® technology, today announced that Joe Epperson, Co-Founder and Chief Executive Officer of MaxPoint, will present at the Needham Emerging Technology Conference, to be held at the Westin Grand Central Hotel in New York on Wednesday, May 18, 2016 at 10:00 AM ET.

A live audio webcast of the presentation will be available at: http://wsw.com/webcast/needham77/mxpt and will subsequently be available on the MaxPoint investor relations website at: http://ir.maxpoint.com.

About MaxPoint

MaxPoint is a marketing technology company that generates hyperlocal intelligence to optimize brand and retail performance. We provide a platform for brands to connect the digital world with the physical world through hyperlocal execution, measurement, and consumer insights.

The company’s proprietary Digital Zip® technology and the MaxPoint Intelligence Platform™ predict the most likely buyers of a specific product at a particular retail location and then execute cross-channel digital marketing programs to reach these buyers. For more information, visit maxpoint.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160504005376/en/

MaxPoint Interactive
Public Relations Contact:
Patrick Foarde, 404-879-9254
[email protected]
or
Investor Relations Contact:
Denise Garcia, 800-916-9960
[email protected]

Source: MaxPoint Interactive

You May Also Be Interested In

• Liberty Partners Releases Institutional Strategy Report Ahead of Potential Anthropic IPO
• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTI
• TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial